

# 100,000 Genomes Project

Monday 8th December 2014

Dr Tom Fowler  
Director of Public Health

[www.genomicsengland.co.uk](http://www.genomicsengland.co.uk)

# About the 100,000 Genomes Project

- 100,000 whole genome sequences of NHS patients with rare inherited disease, cancers and pathogens



- Project announced by the Prime Minister, David Cameron in December 2012
- An Olympic Legacy
- Genomics England announced by Secretary of State for Health during NHS 65<sup>th</sup> Anniversary Celebrations - July 2013

# Rare Inherited Disease Cancer Pathogens





# Genomics England Pilots

- Phase 1 - Sequencing and Annotation Competition – finished
- 4 providers 15 samples Testing Sequencing QA and annotation
- Phase 2a - 2000 Rare Disease WGS- 30x depth – over 2014
- Partnering NIHR BioResource and Translational Research Collaborative- 5 centres - 2000+ patients since November 2013.
- Phase 2b - 3000 Cancer Patients (Lung, Breast, Ovary, Prostate, Colon and Leukaemia) over 2014-15
- Somatic (60-80x) and germline (30-40x) – tendering now
- Optimise Molecular Pathology pipeline
- Pathogens will be with Public Health England

Phase 3 - 15k in 2015, 25k in  
2016, 45k in 2017



# The case for deep phenotypic data



# Genomic Medicine Centres



**NHS ENGLAND**

INVITATION TO TENDER

STAGE TWO ITT


NHS GENOMIC MEDICINE CENTRE SELECTION - WAVE 1

- Designated local NHS Lead and extended team
- Capacity and capability networks
- High fidelity phenotypes
- Access to data and samples
- February start date

# Genomics England Clinical Interpretation Partnership



# Why do we need a Clinical Interpretation Partnership?



**Securing Patient Benefit**

# Genomics England Clinical Interpretation Partnership

- Drive up the fidelity of clinical interpretation of WGS
- UK –led self-organised into domains
- Partnership with researchers, the NHS and Trainees with skills.
- Can bring international collaborators
- Possible formation of a precompetitive consortium of a limited number of industry partners.
- All data generated contributes to the Genomics England Dataset and are available to all.
- Designed to accelerate academic/industry partnership and development of diagnostics and therapies.
- Recognises that to get to a therapy will require significant additional R&D which we aim to stimulate here in the UK.
- IP owned by Genomics England but freely licensed

# Genomics England Clinical Interpretation Partnership

## Rare Disease, Cancer and Infection Domains

Organised in Disease Domains	Key functions and outputs
UK led - steering group	Appoint domain leader & sub-groups
Genomics England Chief Scientist's Team	Oversight, informatics and logistics for the programme
Multiple phenotypic sub-groups	Deeper phenotyping & extend programme
Functional characterisation Multi-omics	Single cell or model functional studies RNA, epigenetics, proteomics
Analysts and Bio-informaticians	Novel analytic approaches
Interpretation - NHS and PHE teams and Researchers	Highest fidelity dynamic reporting system Integrated Multi-Disciplinary Team
Training - HEE/GECIP trainees	Genomic Medicine Academy
Precompetitive industry partners	Academic/Industry Collaboration

# Genomics England – The main programme



## NHS Genomic Medicine Centres

Rare diseases, cancers and pathogens

Broad consent, characteristics, molecular pathology and samples

DNA & multi-omics  
Repository

Sequencing Centre  
Wellcome Trust £27m

**Refreshable identifiable  
Clinical Data  
Life-course registry**

**Linked to anonymised  
Whole Genome Sequence**

Primary Care  
Hospital episodes  
Cancer Registries  
Rare Disease  
Registries  
Infectious Disease  
Mortality data  
Patient entry



**MRC £24m Research Data Infrastructure (GeCIP)**  
**Sequential builds of pseudonymised data and WGS**  
**Safe haven- users work within**

Annotation & QC  
Scientists & SMEs  
Product  
comparison

Fire wall  
Patient data stays in safe haven

Only processed  
results pass outside

Clinicians &  
Academics

Training &  
capacity

Industry

# Establishment Phase

- Illumina Partnership
- NHS Genome Sequencing Centre – £27m from Wellcome
- MRC Award of £24m to establish the UK Data Infrastructure for Genomic Medicine



Partnership of QMUL, UCL, The Farr, Oxford Big Data, UK Biobank, Sanger, EBI, Cambridge, Kings

PARTNERSHIP & INNOVATION  
WITHOUT REINVENTION

# Genomic Medicine

- Specialist genetics, pathology and specialist clinical workforce in Genomic Medicine
- Increase in specialised scientific training fellows funded over 3/5 years:
  - Molecular Pathology including Infections and Pathogens
  - Genetics / genomics
  - Bioinformatics
- Commission bioinformatics workshops in conjunction with partners
- Develop specialist on line on-line learning and an MSc in Genomic Medicine
- Develop an MSc in Genomic Medicine
- CPD access to MSc modules for specialist practitioners

# Genomics England

- 100,000 WGS of NHS patients
- Working with NHS, academics and industry to drive Genomic Medicine into the NHS
- Support that with education
- Leave a legacy of NGS Centres, sample pipeline and biorepository, large-scale data store that makes this usable by the NHS
- New diagnostics and therapies and opportunities for patients
- By end of 2017